Open access
Sep 2026
HER2 amplification as a resistance mechanism to osimertinib and its successful treatment with trastuzumab deruxtecan: a case report
Acquired resistance to osimertinib in EGFR-mutant advanced non-small cell lung cancer is inevitable, and management following progression remains an evolving clinical challenge. HER2 amplification is a recognised but underreported off-target resistance mechanism, and its optimal management is not yet established. Tra...
Mansi Sharma, Ritwika Choudhury, Abhinav Dewan et al.
· Frontiers in Oncology · 0 citations